Sunday, April 18, 2021

Keys to Successful Discontinuation of Antipsychotic Medication

Qualitative study finds that both internal resources and systemic factors play a role in antipsychotic discontinuation outcomes.

The BBC, Harrow, and a Public Left in the Dark

The recent report by the BBC on medication-free treatment in Norway, when viewed in conjunction with the media silence on Martin Harrow's latest publication, reveals why the public remains misinformed about the long-term effects of antipsychotics.

A Short History of Tardive Dyskinesia: 65 Years of Drug-Induced Brain Damage That Rolls...

Psychiatry has long turned a blind eye to the full scope of harm associated with TD. New TD drugs "work" by further impairing brain function.

The Latest “Breakthrough Therapy”: Expensive New Drugs for Tardive Dyskinesia

The increased prescribing of antipsychotics, which frequently cause a brain injury that manifests as tardive dyskinesia, has provided pharmaceutical companies with a lucrative new market opportunity.

Anticholinergic Drugs Increase Risk of Cognitive Decline

A new study finds that anticholinergic drugs, like antidepressants and antipsychotics, are associated with mild cognitive decline.
antipsychotic drugs

Antipsychotic Augmentation Increases Risk of Death

A new study finds that adding an antipsychotic to existing antidepressant treatment is associated with a 45% increased risk of early death.

Greater Exposure to Antipsychotics Associated with Worse Long-Term Outcomes

A new study finds adverse long-term consequences associated with the increased use of antipsychotics in first-episode psychosis.

Very Slow Taper Best for Antipsychotic Discontinuation

An article in JAMA Psychiatry advises very slow tapering for best results when discontinuing antipsychotic drugs.

An FDA Whistleblower’s Documents: Commerce, Corruption, and Death

In 2008, a reviewer of psychiatric drugs at the FDA, Ron Kavanagh, complained to Congress that the FDA was approving a new antipsychotic that was ineffective and yet had adverse effects that increased the risk of death. Twelve years later, a review of the whistleblower documents reveal an FDA approval process that can lead to the marketing of drugs sure to harm public health.

Antipsychotics Associated with Severe COVID-19 and Fatal Outcomes

A new study has found a strong association between antipsychotic drugs and higher rates of severe cases of COVID-19.

For People “At Risk for Psychosis,” Antipsychotics Associated with Worse Outcomes

Researchers studied whether antipsychotics could prevent transition to full psychosis and found that the drugs worsened outcomes.

Randomized Controlled Trial Confirms That Antipsychotics Damage the Brain

A new study published in JAMA Psychiatry connects antipsychotics with damage to the brain in multiple areas.

Do Antipsychotics Protect Against Early Death? A Review of the Evidence

Psychiatry is now claiming that research has shown that antipsychotics reduce mortality among the seriously mentally ill. A critical review of the literature reveals that this claim is best described as the the field's latest "delusion" about the merits of these drugs.

Antipsychotic Trials Show Increasing Placebo Response and Declining Drug Response

A new review of antipsychotic trials conducted over the last 24 years finds that the placebo response rate is steadily increasing, and drug response is decreasing.

Does Longer Duration of Untreated Psychosis Cause Worse Outcomes?

New research counters the long-held assumption that a longer duration of untreated psychosis is associated with worse outcomes.

Largest Survey of Antipsychotic Experiences Reveals Negative Results

A new survey exploring antipsychotic user experience finds that more than half of the participants report only negative experiences.

Review Explores First-Person Experiences of People Taking Antipsychotics

A new systematic review finds that patients report reduced symptoms but also loss of self and agency while taking antipsychotics.

The Charade of New Drug Approvals for Schizophrenia

The FDA recently approved lumateperone for schizophrenia. A review of the clinical trials reveals a testing process that is fatally flawed, and a new drug coming to market that doesn't provide a clinically meaningful benefit.

Relapse in Antipsychotic Drug Trials is Poorly Defined

There is a lack of consensus in the definition of ‘relapse’ across randomized controlled trials of antipsychotic maintenance treatment for schizophrenia and psychosis.
digital antipsychotic

The Rise of the Digital Asylum

The digital pill Abilify MyCite, which is now being introduced into the market, foretells of a future where such technology is used to monitor the behavior, location and "medication compliance" of a person 24 hours a day.

How Do We Test the Effects of Long-Term Exposure to Antipsychotics?

A new attempt to study the neurological effects of long-term exposure to antipsychotics uses healthy volunteers on minimal doses for 15 days.

How Exercise Can Help With First Episode Psychosis

New study examines the experiences of people utilizing an exercise program following a first-episode psychosis.

Review Finds FDA Approval of Digital Antipsychotic Misguided

The approval of the digital antipsychotic may open the door for more pharmaceutical company profits without evidence of benefits to patients.
A box of Zyprexa pills.

Lack of Clear Guidelines Prevent Clinicians from Reducing Antipsychotics

A recently published study from noted critical psychiatry expert Joanna Moncrieff explored the barriers that prevent clinicians from helping service users in discontinuing or...
Yellow sign reading "Cognitive Hazard"

Discontinuation of Antipsychotics Improves Cognitive Functioning

A study, recently published in Psychological Medicine, examined the cognitive functioning of individuals with schizophrenia who discontinued antipsychotics, and those who maintained their antipsychotic...

Follow Us

19,639FansLike
11,994FollowersFollow
0SubscribersSubscribe